default author photo

Hiromichi Nakajima

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

40

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study

Number of pages: 38 Posted: 24 Oct 2025
Miki Hayakawa, Hiromichi Nakajima, Kenichi Harano, Shogo Watanabe, Saki Tsuchimochi, Mao Uematsu, Misao Fukuda, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Masashi Wakabayashi, Kazuaki Takahashi, Hiroshi Tanabe and Toru Mukohara
affiliation not provided to SSRN, affiliation not provided to SSRN, National Cancer Center Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, National Cancer Center Hospital East, National Cancer Center Hospital, affiliation not provided to SSRN, National Cancer Center Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN and National Cancer Center Hospital East - Department of Breast and Medical Oncology
Downloads 40 (1,222,651)

Abstract:

Loading...

ovarian cancer, PARP inhibitor, platinum‑free interval, bevacizumab, second‑line chemotherapy, homologous recombination deficiency (HRD)